Form 4: CytoDyn Director Karen Brunke Reports Stock Option Grant

Director Karen Brunke reports the grant of non-qualified stock options for 800,000 shares of CytoDyn Inc. common stock.

Summary

• Karen Brunke, a director of CytoDyn Inc., filed a Form 4 on October 30, 2024, reporting a transaction.
• The transaction involves the grant of non-qualified stock options to purchase 800,000 shares of CytoDyn Inc. common stock at an exercise price of $0.13 per share.
• The options were granted on October 28, 2024, and expire on October 28, 2034.
• 266,664 shares vested immediately, with the remaining shares vesting in equal monthly installments from October 2024 through May 2025.
• Brunke also has a Limited Power of Attorney appointing Jacob Lalezari, Mitchell Cohen, Tyler Blok, and Nathan Fox to act on her behalf for SEC filings related to CytoDyn securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates continued investment in the company by a director and aligns interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the option grant suggests an expectation of future value creation.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant and vesting schedule are typical for director-level compensation, but would need to be compared to similar companies of CytoDyn's size and stage of development to fully assess.
• Companies like Amgen, Gilead, and Biogen also use stock options extensively, but their specific terms and conditions vary based on individual performance and company goals.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with increasing shareholder value.
• Employees may see it as a sign of confidence in the company's future.

Key Dates